State of Wisconsin Investment Board bought a new stake in shares of Edge Therapeutics, Inc. (NASDAQ:EDGE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,000 shares of the biotechnology company’s stock, valued at approximately $154,000.

A number of other institutional investors and hedge funds have also modified their holdings of EDGE. Eagle Asset Management Inc. raised its stake in Edge Therapeutics by 4.4% during the 1st quarter. Eagle Asset Management Inc. now owns 899,968 shares of the biotechnology company’s stock valued at $8,198,000 after purchasing an additional 37,536 shares during the period. Renaissance Technologies LLC bought a new stake in Edge Therapeutics during the 1st quarter valued at approximately $297,000. TFS Capital LLC bought a new stake in Edge Therapeutics during the 1st quarter valued at approximately $209,000. Vanguard Group Inc. raised its stake in Edge Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after purchasing an additional 19,973 shares during the period. Finally, Spark Investment Management LLC bought a new stake in Edge Therapeutics during the 1st quarter valued at approximately $157,000. 49.38% of the stock is currently owned by institutional investors.

Edge Therapeutics, Inc. (NASDAQ:EDGE) opened at 9.48 on Friday. Edge Therapeutics, Inc. has a 12-month low of $7.30 and a 12-month high of $13.50. The firm’s 50-day moving average price is $10.45 and its 200 day moving average price is $9.86. The stock’s market cap is $292.47 million.

Edge Therapeutics (NASDAQ:EDGE) last announced its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). Analysts anticipate that Edge Therapeutics, Inc. will post ($1.87) EPS for the current year.

EDGE has been the topic of several recent analyst reports. BidaskClub raised Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded Edge Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 3rd.

COPYRIGHT VIOLATION WARNING: “State of Wisconsin Investment Board Takes $154,000 Position in Edge Therapeutics, Inc. (EDGE)” was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/state-of-wisconsin-investment-board-takes-154000-position-in-edge-therapeutics-inc-edge.html.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $10.19, for a total transaction of $76,425.00. Following the completion of the transaction, the insider now owns 132,736 shares of the company’s stock, valued at $1,352,579.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $10.37, for a total value of $25,925.00. Following the transaction, the chief executive officer now directly owns 117,736 shares of the company’s stock, valued at approximately $1,220,922.32. The disclosure for this sale can be found here. Insiders have sold 31,000 shares of company stock valued at $319,190 in the last three months. Insiders own 36.19% of the company’s stock.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Want to see what other hedge funds are holding EDGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edge Therapeutics, Inc. (NASDAQ:EDGE).

Institutional Ownership by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.